安德罗格拉菲斯 (Andrographis paniculata) 通过增强胰岛素敏感性和调高威斯塔尔大鼠GLUT 4表达来改善葡萄糖调节
W A Saka1, O S Oyekunle1, T M Akhigbe2,3
1Department of Physiology, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Frontiers in nutrition
|November 15, 2024
概括
安德罗格拉菲斯 (Andrographis paniculata) 通过增强糖性酶活性和GLUT 4表达,改善健康大鼠的葡萄糖代谢和胰岛素敏感性. 建议小心预防非糖尿病人的低血糖症.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢健康 代谢健康
- 草药是一种草药.
背景情况:
- 有限的研究存在于Andrographis paniculata (Burm.f.) 的影响. 在非糖尿病状态下的Nees [Acanthaceae].
- 传统上,Andrographis paniculata因其潜在的低血糖特性而受到认可.
研究的目的:
- 在非糖尿病大鼠中研究A. paniculata的低血糖作用.
- 探索A. paniculata对糖分酶和GLUT 4蛋白表达的影响,作为一种潜在的作用机制.
主要方法:
- 20只雄性Wistar大鼠被分为对照组和A. paniculata (500 mg/kg) 治疗组进行了35天的治疗.
- 评估了胰岛素敏感性,葡萄糖调节,动脉动脉性脂质失调症,肝/肌肉氧化还原状态,甘油酶活性,GLUT 4蛋白表达和氧化水平.
主要成果:
- A. paniculata的治疗显著改善了胰岛素敏感性 (HOMA-β,HOMA-S,TyG指数,HOMA-IR) 和葡萄糖调节 (禁食血糖,HbA1c).
- 观察到动脉动脉性脂质失调症 (AIP,CRI-I) 的改善,增强的氧化还原状态,增加的糖分解酶活性,高调的GLUT 4表达和升高的氧化水平.
结论:
- A. paniculata通过增强胰岛素敏感性和上调糖分酶和GLUT 4蛋白质来积极影响葡萄糖代谢和利用.
- A. paniculata可能有助于预防胰岛素耐药性和2型糖尿病,但需要小心,以避免非糖尿病患者出现低血糖症.
相关概念视频
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K


